Kymriah is set to decide whether US , a gene therapy developed by Spark Spark for people with retinal disorders, should be granted approval. Dispensed via injection, the Luxturna therapy corrects the RPE65 gene, enabling the creation of a protein essential to eyesight. They might be losing ground, as Spark has announced plans to set up a program to help patients cover out-of-pocket costs like travel to Spark-proffering facilities. Spark said that Two people who have undergone the treatment experienced an improvement in their vision. However, Luxturna is not a complete cure, and faces competition from rival treatments costing around $700,000 .
Kymriah is set to decide whether US , a gene therapy developed by Spark Spark for people with retinal disorders, should be granted approval. Dispensed via injection, the Luxturna therapy corrects the RPE65 gene, enabling the creation of a protein essential to eyesight. Spark said that Two people who have undergone the treatment experienced an improvement in their vision. However, Luxturna is not a complete cure, and faces competition from rival treatments costing around $700,000 .